Search Results - "Ruiz Extremera, A."

Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation by Aguilar-Quesada, R, Muñoz-Gámez, J A, Martín-Oliva, D, Peralta-Leal, A, Quiles-Pérez, R, Rodríguez-Vargas, J M, Ruiz de Almodóvar, M, Conde, C, Ruiz-Extremera, A, Oliver, F J

“…Post-translational modification of proteins by poly(ADP-ribosyl)ation is involved in the regulation of a number of biological functions. While an 18 member…”
Get more information

Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of Hepatitis C Virus Genotype 1 and Their Relationships to Pegylated Interferon-Ribavirin Treatment Responses by MUNOZ DE RUEDA, P, CASADO, J, PATON, R, QUINTERO, D, PALACIOS, A, GILA, A, QUILES, R, RUIZ-EXTREMERA, J. Leon A, SALMERON, J

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children by Ruiz-Extremera, A, Pavón-Castillero, E J, Florido, M, Muñoz de Rueda, P, Muñoz-Gámez, J A, Casado, J, Carazo, A, Quiles, R, Jiménez-Ruiz, S M, Gila, A, Luna, J D, León, J, Salmerón, J

“…There is evidence that maternal viral load of HCV during delivery influences the risk for Mother-to-child transmission (MTCT), but this does not explain all…”
Get full text

Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells by Muñoz-Gámez, J.A, Quiles-Pérez, R, Ruiz-Extremera, A, Martín-Álvarez, A.B, Sanjuan-Nuñez, Laura, Carazo, A, León, Josefa, Oliver, F.J, Salmerón, J

“…Abstract The purpose of this study was to investigate whether PARP-1 inhibition sensitizes human liver cancer cell lines to doxorubicin treatment. Both the…”
Get full text

Effects of manual therapy on treatment duration and motor development in infants with severe nonsynostotic plagiocephaly: a randomised controlled pilot study by Cabrera-Martos, I., Valenza, M. C., Valenza-Demet, G., Benítez-Feliponi, A., Robles-Vizcaíno, C., Ruiz-Extremera, A.

“…Purpose Despite growing evidence regarding nonsynostotic plagiocephaly and their repercussions on motor development, there is little evidence to support the…”
Get full text

Nanoengineering of doxorubicin delivery systems with functionalized maghemite nanoparticles by Rudzka, Katarzyna, Viota, Julián L., Muñoz-Gamez, J.A., Carazo, A., Ruiz-Extremera, A., Delgado, Ángel V.

“…•Superparamagnetic iron oxide nanoparticles were employed for delivery of antitumor agents.•These magnetic cores were coated successively with silica and gold…”
Get full text

The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response by Muñoz de Rueda, P., Jiménez-Ruiz, S. M., Quiles, R., Pavón-Castillero, E. J., Muñoz-Gámez, J. A., Casado, J., Gila, A., Ruiz-Extremera, A., Salmerón, J.

“…Our previous data show that hepatitis C virus (HCV) genotype 1 patients expressing the HLA-DQB1 * 0301 allele have a combined response probability of 69%,…”
Get full text

P0463 : Influence of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligands on vertical transmission and chronicity of hepatitis C virus in children by Pavon-Castillero, E.-J, Ruiz-Extremera, A, Florido, M, Muñoz de Rueda, P, Muñoz-Gamez, J.-A, Casado, J, Carazo, A, Quiles, R, Gila, A, Jimenez-Ruiz, S, Martin, A.B, León, J, Salmeron, J

Get full text

Drug utilization pattern in children and off-label use of medicines in a pediatric intensive care unit by Blanco-Reina, E, Medina-Claros, A F, Vega-Jiménez, M A, Ocaña-Riola, R, Márquez-Romero, E I, Ruiz-Extremera, Á

“…This study aims to assess the prescription profile and license status of drugs used in a neonatal and pediatric intensive care unit (NPICU). A prospective…”
Get more information

Clinical profile and evolution of infants with deformational plagiocephaly included in a conservative treatment program by Cabrera-Martos, I., Valenza, M. C., Benítez-Feliponi, A., Robles-Vizcaíno, C., Ruiz-Extremera, A., Valenza-Demet, G.

“…Purpose The aim of this study was to evaluate the results of a conservative intervention in infants with plagiocephaly according to their specific clinical…”
Get full text

Histological and immunohistochemical assessment of liver biopsies in morbidly obese patients by Caballero, T, Gila, A, Sánchez-Salgado, G, Muñoz de Rueda, P, León, J, Delgado, S, Muñoz, J A, Caba-Molina, M, Carazo, A, Ruiz-Extremera, A, Salmerón, J

“…To study liver lesions in morbidly obese patients who underwent liver biopsy at the time of bariatric surgery to define histological lesions, especially…”
Get full text

Post-transfusional hepatitis in neonates hospitalized in a Neonatal Intensive Care Unit by Ruiz Extremera, A, Salmerón, J, Torres, M L, Muñoz de Rueda, P, Ocete, E, Luna, J D

“…To assess the significance of increased serum transaminase levels in neonates admitted to a Neonatal Intensive Care Unit and its relationship with blood…”
Get full text

Hepatotoxicity due to drugs or natural products in children by Ocete Hita, E, Martín García, J A, Giménez Sánchez, F, Flores González, J C, Abril Molina, A, Salmerón Escobar, J, Ruiz Extremera, A

“…The incidence of adverse drug reactions in children has recently been established at 15.1 reactions per 1000 children. This represents 2% of admissions to a…”
Get full text

891 IMPORTANCE OF HLA-DQB10301 AS PREDICTIVE FACTOR OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS WITH CHRONIC HEPATITISC (CHC), GENOTYPE-1, TREATED WITH PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) by de Rueda, P. Muñoz, López-Nevot, M.A, Casado, J, Martín-Casares, A, Rodríguez, L, Quiles, R, Romero-Gómez, M, Diago, M, Martín, A, Muñoz, J.A, Ruiz-Extremera, A, Escobar, J. Salmerón

Get full text

344 POLY (ADP-RIBOSE) POLIMERASE-1 (PARP-1), NEW TARGET FOR HEPATIC CARCINOMA TREATMENT by Quiles, R, Munoz-Gamez, J.A, Ruiz-Extremera, A, Martin-Alvarez, A.B, Sanjuan-Nunez, L, de Rueda, P. Munoz, Salmeron, J

Get full text

Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors by SALMERON, F. J, PALACIOS, A, PEREZ-RUIZ, M, TORRES, C, OYONARTE, S, FERNANDEZ-MONTOYA, A, RUIZ-EXTREMERA, A

“…The epidemiology associated with hepatitis C virus (HCV) infection, serologic reactivity, and hepatic disease related to anti-HCV-positive donors of Granada…”
Get full text

1322 RELATION BETWEEN THE ADIPOCYTE HYPERTROPHY DEGREE AND ADIPOSE TISSUE MACROPHAGE INFILTRATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) PROGRESSION IN MORBID OBESITY by Carazo Gallego, A, Sanjuan, L, Caba-Molina, M, Caballero, T, Muñoz-Gámez, J.A, Gila, A, González-Rubio, J, Membrives, A, Ana, M, Quiles, R, López-Viota, J, De la Mata, M, Ruiz- Escolano, E, Ruiz-Extremera, A, Salmerón, J

Get full text

Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial by Salmerón, J., Diago, M., Andrade, R., Pérez, R., Solá, R., Romero, M., De La Mata, M., Granados, R., Ruiz-Extremera, A., Mu¯oz de Rueda, P.

“…The benefit of the triple therapy (interferon + amantadine + ribavirim) is still unknown. The efficacy of induction doses of interferon‐α‐2a monotherapy or in…”
Get full text

Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation by Viota, J.L., Carazo, A., Munoz-Gamez, J.A., Rudzka, K., Gómez-Sotomayor, R., Ruiz-Extremera, A., Salmerón, J., Delgado, A.V.

“…Gemcitabine is a chemotherapy drug used in different carcinomas, although because it displays a short biological half-life, its plasmatic levels can quickly…”
Get full text

Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial by Salmerón, J, Diago, M, Andrade, R, Pérez, R, Solá, R, Romero, M, de la Mata, M, Granados, R, Ruiz-Extremera, A, Muñoz de Rueda, P

“…The benefit of the triple therapy (interferon + amantadine + ribavirim) is still unknown. The efficacy of induction doses of interferon-alpha-2a monotherapy or…”
Get full text